Compare AbCellera Biologics Inc (ABCL) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Zeta Global Holdings Corp — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Zeta Global Holdings Corp trades at $21.41 (market cap $5.45B). The key difference: Zeta Global Holdings Corp is far larger — about 2.3× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Zeta Global Holdings Corp nearer its low. Which is the better fit depends on your goals.
| ABCL | ZETA | |
|---|---|---|
Market Cap | $2.35B | $5.45B |
Sector | Health | Technology |
52-Week High | $8.12 | $25.24 |
52-Week Low | $2.78 | $14.00 |
Enterprise Value | $1.99B | $5.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ZETA trades at $21.82, up 5.46% over the past 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $27.50. Recent earnings beats and a strategic AI partnership with Palantir highlight strong operational momentum, though negative net income and cash flow remain concerns. The stock shows robust revenue growth and high gross margins, supported by positive media coverage and institutional interest.
The outlook for ZETA is cautiously optimistic, driven by AI integration and consistent earnings outperformance. Key risks include persistent unprofitability and competitive pressures in the marketing technology sector. Investors should weigh the high valuation multiples against growth potential, with analyst sentiment strongly favoring buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
